LivingGLP1
Study S001045

Pilot Study of the Effect of Liraglutide on Weight Loss and Gastric Functions in Obesity

Registration

Registration
NCT02647944
Study type
INTERVENTIONAL
Allocation
RANDOMIZED
Phase
PHASE2
Masking
DOUBLE
Status
COMPLETED
Enrollment
40
Start
2015-12-18
Primary completion
2016-12-30
Lead sponsor
Mayo Clinic
Conditions
Obesity
Interventions
DRUG:Liraglutide; DRUG:Placebo
Results posted
TRUE
Secondary identifiers
NIH:R56DK067071; NIH:UL1TR000135

Registered primary outcomes

  • Gastric Emptying of Solids Half-time (T1/2) at 5 Weeks [5 weeks]
  • Gastric Emptying of Solids Half-time (T1/2) at 16 Weeks [16 weeks]

Linked records (4)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
RecordTitleYearDesignIdentifiersLink basis
R0000439Appetite Suppression by GLP-1 Receptor Agonists: Role of Delayed Gastric Emptying.
Friedman MI, Obesity (Silver Spring, Md.)
2026Randomized trialPMID 42392577DOIcites ClinicalTrials.gov:NCT02647944; registry reference DERIVED:42392577
R0016746Effects of liraglutide on gastrointestinal functions and weight in obesity: A randomized clinical and pharmacogenomic trial.
Maselli D, Obesity (Silver Spring, Md.)
2022Randomized trialPMID 35894080DOIcites ClinicalTrials.gov:NCT02647944; registry reference DERIVED:35894080
R0019135GLP-1 Analog Modulates Appetite, Taste Preference, Gut Hormones, and Regional Body Fat Stores in Adults with Obesity.
Kadouh H, The Journal of clinical endocrinology and metabolism
2020Randomized trialPMID 31665455DOIcites ClinicalTrials.gov:NCT02647944; registry reference DERIVED:31665455
R0022992Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomised, placebo-controlled pilot trial.
Halawi H, The lancet. Gastroenterology & hepatology
2017Randomized trialPMID 28958851DOIcites ClinicalTrials.gov:NCT02647944; registry reference BACKGROUND:28958851